PT - JOURNAL ARTICLE AU - MI JIN OH AU - DONG-YEOP SHIN AU - YOUNGIL KOH AU - JUNSHIK HONG AU - INHO KIM AU - SUNG-SOO YOON AU - JA MIN BYUN TI - A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients AID - 10.21873/invivo.12299 DP - 2021 Jan 01 TA - In Vivo PG - 617--622 VI - 35 IP - 1 4099 - http://iv.iiarjournals.org/content/35/1/617.short 4100 - http://iv.iiarjournals.org/content/35/1/617.full SO - In Vivo2021 Jan 01; 35 AB - Background/Aim: For intermediate risk acute myeloid leukemia patients, allogeneic hematopoietic stem cell transplantation (alloSCT) and chemotherapy are equally recommended as consolidation after first complete remission (CR1). In real-world, alloSCT might not be readily available, but there is paucity of data on the optimal timing of alloSCT for these patients. Patients and Methods: In this pilot study, we compared the outcomes of 13 patients undergoing alloSCT in CR1 with 13 patients undergoing alloSCT after relapse (non-CR1) to examine whether upfront alloSCT yields a better prognosis. Results: There were no differences between the two groups with regards to relapse-free survival (p=0.507) and overall survival (p=0.798). There were more chronic graft-versus-host-disease (GVHD) in the CR1 group compared to the non-CR group (p=0.001), but no difference in acute GVHD. Conclusion: The outcome of alloSCT after relapse is not inferior to that of alloSCT in CR1, supporting the role of alloSCT after relapse in the setting of limited donors and resources.